Mass cytometry reveals immune atlas of urothelial carcinoma

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Immunotherapy, particularly PD1/PD-L1 inhibitors, is a second-line treatment for urothelial carcinoma.
• Despite significant efficacy, response rates to current immunotherapies remain suboptimal.
• The tumor immune microenvironment critically influences immunotherapy outcomes, but its detailed profile in urothelial carcinoma is not well understood.

Purpose of the Study:

• To comprehensively characterize the tumor immune microenvironment in urothelial carcinoma.
• To identify novel biomarkers and therapeutic targets for improving immunotherapy efficacy.
• To investigate the role of T cells and tumor-associated macrophages in the context of immunotherapy.

Main Methods:

• Mass cytometry was employed for in-depth immunoassay on 12 urothelial carcinoma and 14 paratumor tissue samples.
• Single-cell analysis was used to identify diverse T-cell and tumor-associated macrophage phenotypes.
• Expression profiles of key immune markers, including PD1, PD-L1, CD38, and exhausted T-cell markers, were analyzed.

Main Results:

• Analysis revealed 71 T-cell phenotypes and 30 tumor-associated macrophage phenotypes.
• Almost all T cells within the tumor tissue exhibited markers of exhaustion.
• CD38 expression was significantly higher on tumor-associated macrophages (TAMs) compared to PD-L1, and CD38+ TAMs correlated with immunosuppression.

Conclusions:

• The tumor immune microenvironment in urothelial carcinoma is characterized by exhausted T cells and immunosuppressive CD38+ TAMs.
• CD38+ TAMs represent a potential therapeutic target, possibly offering advantages over PD1/PDL1 inhibition.
• This study provides valuable insights into the urothelial carcinoma immune landscape and identifies CD38 as a promising biomarker and target for future immunotherapy development.